Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
SINGAPORE, Jan. 28 (Korea Bizwire) — In the phase II CodeBreak 100 trial, sotorasib provided durable clinical benefit with a favorable safety profile in patients with pretreated non-small cell lung cancer (NSCLC) and who harbor KRAS p.G12C mutations, validating CodeBreak 100’s phase I results, according to research presented today at the International Association for the Study of [...]
